

TECHNICAL DATA

Peripheral Stent:

- Polymer Free Self-Expanding DES
- Stent material: Nitinol (Nickel Titanium alloy)
- Strut surface coating: integral Bio Inducer Surface (BIS)
- 6 tantalum radiopaques markers

Drug and elution information:

- Amphilimus™ formulation: Sirolimus + Fatty Acid
- Drug release controller: Abluminal Reservoir Technology - Sustained elution up to 2-3 months

Device:


- Over The Wire system (OTW)
- Introducer sheath compatibility: 6F
- Guidewire compatibility: 0.035"
- Usable Catheter Lengths (UCL): 85 and 135 cm

Ordering Information Catheter Length 85 cm

L (mm)	20	40	60	80	100	120	150
6	ICNI6020S	ICNI6040S	ICNI6060S	ICNI6080S	ICNI60100S	ICNI60120S	ICNI60150S
7	ICNI7020S	ICNI7040S	ICNI7060S	ICNI7080S	ICNI70100S	ICNI70120S	ICNI70150S
8	ICNI8020S	ICNI8040S	ICNI8060S	ICNI8080S	ICNI80100S	ICNI80120S	ICNI80150S

Ordering Information Catheter Length 135 cm

L (mm)	20	40	60	80	100	120	150
6	ICNI6020L	ICNI6040L	ICNI6060L	ICNI6080L	ICNI60100L	ICNI60120L	ICNI60150L
7	ICNI7020L	ICNI7040L	ICNI7060L	ICNI7080L	ICNI70100L	ICNI70120L	ICNI70150L
8	ICNI8020L	ICNI8040L	ICNI8060L	ICNI8080L	ICNI80100L	ICNI80120L	ICNI80150L



NiTiDES™

Manufactured by CID S.p.A.
Strada per Crescentino, sn - 13040 Saluggia (VC), Italy
CID S.p.A. member of Alvimedica Group

www.alvimedica.com

This product is CE marked.

Please consult product labels and package inserts for indications, contraindications, hazards, warnings, cautions and instruction for use.



PERIPHERAL VASCULAR

NiTiDES™

Amphilimus™ (Sirolimus + Fatty Acid)
eluting Peripheral Self-Expanding stent



Made in Italy

CID S.p.A. member of Alvimedica Group

2021/05 IC0701555724/0



The images shown within this document are of a purely illustrative nature and are not intended to depict reality

©2021, Alvimedica. All rights Reserved.





TECHNOLOGY RATIONAL UNIQUE FEATURES

The proprietary polymer-free **Abluminal Reservoir Technology** allows a sustained drug release, exclusively towards the vessel wall, up to 3 months, eliminating the renowned drawback associated to the polymers.



Amphilimus™

The **Amphilimus™ formulation** (Sirolimus + Fatty Acid) enhances drug bioavailability, permeability and maximizes product overall safety and efficacy.




BIS coating

The **Bio Inducer Surface** is an ultra thin film (<0.3µm) of pure carbon coating integrally applied to the NiTiDES™ stent platform. Thanks to its haemo- and bio- compatibility, it acts as anti-thrombotic coating and it promotes a fast healing.


CLINICAL PROOF

ILLUMINA is the First In Human study designed to prove NiTiDES™ Safety and Efficacy in the treatment of the Superficial Femoral Artery. The study enrolled 100 patients in 10 centers across Germany, France and Italy.



24 MONTHS STUDY RESULTS: SAFETY & EFFICACY


Major Adverse Event (MAE) Device Oriented



* CEC adjudicated

** 1 Patient, asymptomatic at 1year, had femoral fracture 5 months before 2 years FU visit (Rutherford classes are not CEC adjudicated)

CD-TLR comparison



* Data presented @ LINC 2020 by D. Scheinert

** Data presented @ LINC 2020 by Dr William A.Grey
Comparison provided for educational purpose

The **ILLUMINA** study results stand **NITIDES™** at the top of excellence in today peripheral DES scenario